Scientific Origins
and Company Milestones
Divamics was born from the shared scientific vision of Co Founders Dr. John Zheng and Dr. Hao Liu. Both earned their PhDs in Chemistry from the University of Florida, training within the prestigious AMBER molecular dynamics community — the global gold standard for biomolecular simulation.
During his time in the U.S., Dr. Zheng pioneered the MovableType free energy algorithm. This breakthrough technology secured second place globally in the SAMPL6 drug design challenge and garnered recognition from Nobel Laureate Roald Hoffmann. Its practical utility in industrial drug design was further validated through its commercial integration by QuantumBio. Concurrently, Dr. Liu honed her expertise at Genentech, focusing on data processing and database architecture.
Prior to founding DIVAMICS, Dr. Zheng served as Principal Investigators at Wuhan University of Technology, with Dr. Liu playing a pivotal role in his research group. Their collaborative research, which bridged advanced molecular dynamics with practical drug discovery, laid the rigorous scientific foundation upon which DIVAMICS is built.
Inception & Assembly
- Divamics Established: Formally launched in Suzhou.
- Core Team Assembled: Built a multidisciplinary team of PhDs and medicinal chemists dedicated to solving critical discovery challenges via AI & Molecular Dynamics (MD).
-
2023
Validation & Ecosystem
- "Molecular Movie" Framework: Refined scientific concepts through high-impact publications in MD and AI-driven design.
- Multi-Modality Success: Validated platform capabilities across Small Molecules, Peptides, and Antibodies.
- End-to-End Ecosystem: Established a seamless "Design-to-Validation" network with hospitals and translational partners.
Clinical Breakthroughs
- Phase III Milestone (Peptide): BGM0504 (co-developed with BrightGene) entered Phase III trials; results published in top-tier journals, validating MD-driven peptide design.
- Phase III Milestone (Small Molecule): An EGFR-targeted program reached Phase III, marking a complete journey from mechanistic insight to clinical stage.
- Global Reach: Initiated partnerships in North America and Korea.
Global Expansion & Scale
- Infrastructure: Launched Beijing Computation Center for high-performance computing scale-up.
- Global Hub: Opened Singapore Center for international BD and collaboration.
- JLABS Residency: Joined Johnson & Johnson JLABS to accelerate global innovation.
- Scientific Impact: BGM1812 published in J. Med. Chem.
- Market Leadership: Served 50+ global clients across 80+ pipelines with an ~80% repeat business rate.
Future Outlook
Building the next-generation "Molecular Engineering Factory" — Mechanism-Driven, Science-First.
Built on Trust
Recognized
by the Industry
Since 2021, Divamics has garnered numerous accolades from government bodies, professional institutions, and industry associations. These honors span categories including technological innovation, corporate growth, and leadership excellence.
We view these recognitions not merely as achievements, but as a powerful motivation to remain steadfast in our science-first approach, creating enduring value alongside our partners.
Interested in how this vision connects with your pipeline?
Contact our team to explore collaboration opportunities.
